WVP
LPCN icon

Worth Venture Partners’s Lipocine LPCN Stock Holding History

Worth Venture Partners’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,712
Closed -$69K – 121
2017
Q4 		$69K Sell
1,712
-1,070
-38% -$66.5K 0.08% 87
2017
Q3 		$91K Buy
2,782
+1,411
+103% +$102K 0.08% 101
2017
Q2 		$28K Buy
1,371
+800
+140% +$52.2K 0.02% 100
2017
Q1 		$21K Buy
+571
New +$37K 0.02% 120

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Worth Venture Partners's LPCN Position: Q1 2018 in Review

Worth Venture Partners sold out of Lipocine (LPCN) in Q1 2018, closing a stake of 755 shares — an estimated $44K sold.

Worth Venture Partners first reported a position in LPCN in Q2 2017 and held it in 3 quarters. The position peaked at $171K in Q3 2017. 27 funds tracked by Wall St. Rank hold LPCN as of Q1 2018.

  • Worth Venture Partners reported no remaining Lipocine position as of Q1 2018 after selling out during the quarter.
  • Worth Venture Partners sold 755 Lipocine shares in Q1 2018, an estimated $44K.
  • Worth Venture Partners first reported a position in Lipocine in Q2 2017 and held it in 3 quarters.
  • Worth Venture Partners's Lipocine position peaked at $171K in Q3 2017.
  • 27 funds tracked by Wall St. Rank held Lipocine as of Q1 2018.

Based on Worth Venture Partners's 13F filing for Q1 2018, filed 11 May 2018.